These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 30291111)

  • 41. Microenvironmental immune cell signatures dictate clinical outcomes for PTCL-NOS.
    Sugio T; Miyawaki K; Kato K; Sasaki K; Yamada K; Iqbal J; Miyamoto T; Ohshima K; Maeda T; Miyoshi H; Akashi K
    Blood Adv; 2018 Sep; 2(17):2242-2252. PubMed ID: 30194138
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parameters.
    Lemonnier F; Couronné L; Parrens M; Jaïs JP; Travert M; Lamant L; Tournillac O; Rousset T; Fabiani B; Cairns RA; Mak T; Bastard C; Bernard OA; de Leval L; Gaulard P
    Blood; 2012 Aug; 120(7):1466-9. PubMed ID: 22760778
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The gene expression profile and cell of origin of canine peripheral T-cell lymphoma.
    Owens E; Harris L; Harris A; Yoshimoto J; Burnett R; Avery A
    BMC Cancer; 2024 Jan; 24(1):18. PubMed ID: 38166662
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Increased incidence of adult T cell leukemia-lymphoma and peripheral T cell lymphoma-not otherwise specified with limited improvement in overall survival: a retrospective analysis using data from the population-based Osaka Cancer Registry.
    Fuji S; Kida S; Nakata K; Morishima T; Miyashiro I; Ishikawa J
    Ann Hematol; 2021 Jan; 100(1):157-165. PubMed ID: 33089366
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Oncogenic Vav1-Myo1f induces therapeutically targetable macrophage-rich tumor microenvironment in peripheral T cell lymphoma.
    Cortes JR; Filip I; Albero R; Patiño-Galindo JA; Quinn SA; Lin WW; Laurent AP; Shih BB; Brown JA; Cooke AJ; Mackey A; Einson J; Zairis S; Rivas-Delgado A; Laginestra MA; Pileri S; Campo E; Bhagat G; Ferrando AA; Rabadan R; Palomero T
    Cell Rep; 2022 Apr; 39(3):110695. PubMed ID: 35443168
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Analysis of prognostic factors and comparison of prognostic scores in peripheral T cell lymphoma, not otherwise specified: a single-institution study of 105 Chinese patients.
    Xu P; Yu D; Wang L; Shen Y; Shen Z; Zhao W
    Ann Hematol; 2015 Feb; 94(2):239-47. PubMed ID: 25193354
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pathogenetic and diagnostic significance of microRNA deregulation in peripheral T-cell lymphoma not otherwise specified.
    Laginestra MA; Piccaluga PP; Fuligni F; Rossi M; Agostinelli C; Righi S; Sapienza MR; Motta G; Gazzola A; Mannu C; Sabattini E; Bacci F; Tabanelli V; Sacchetti CA; Barrese TZ; Etebari M; Melle F; Clò A; Gibellini D; Tripodo C; Inghirami G; Croce CM; Pileri SA
    Blood Cancer J; 2014 Nov; 4(11):259. PubMed ID: 25382608
    [TBL] [Abstract][Full Text] [Related]  

  • 48. FoxP3-positive T cell lymphoma arising in non-HTLV1 carrier: clinicopathological analysis of 11 cases of PTCL-NOS and 2 cases of mycosis fungoides.
    Satou A; Asano N; Kato S; Katsuya H; Ishitsuka K; Elsayed AA; Nakamura S
    Histopathology; 2016 Jun; 68(7):1099-108. PubMed ID: 26426838
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The clinical significance of activated p-AKT expression in peripheral T-cell lymphoma.
    Hong JY; Hong ME; Choi MK; Chang W; Do IG; Jo JS; Jung SH; Park S; Kim SJ; Ko YH; Kim WS
    Anticancer Res; 2015 Apr; 35(4):2465-74. PubMed ID: 25862915
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [T-bet in peripheral T-cell lymphoma].
    Wang Z; Zhang DB; Zhou W
    Zhonghua Xue Ye Xue Za Zhi; 2016 Sep; 37(9):779-783. PubMed ID: 27719721
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Identification and characterization of peripheral T-cell lymphoma-associated SEREX antigens.
    Cooper CD; Lawrie CH; Liggins AP; Collins GP; Hatton CS; Pulford K; Banham AH
    PLoS One; 2011; 6(8):e23916. PubMed ID: 21887344
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Peripheral T-cell lymphoma: molecular profiling recognizes subclasses and identifies prognostic markers.
    Rodríguez M; Alonso-Alonso R; Tomás-Roca L; Rodríguez-Pinilla SM; Manso-Alonso R; Cereceda L; Borregón J; Villaescusa T; Córdoba R; Sánchez-Beato M; Fernández-Miranda I; Betancor I; Bárcena C; García JF; Mollejo M; García-Cosio M; Martin-Acosta P; Climent F; Caballero D; de la Fuente L; Mínguez P; Kessler L; Scholz C; Gualberto A; Mondéjar R; Piris MA
    Blood Adv; 2021 Dec; 5(24):5588-5598. PubMed ID: 34592752
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Peripheral T cell lymphoma, not otherwise specified (PTCL-NOS). A new prognostic model developed by the International T cell Project Network.
    Federico M; Bellei M; Marcheselli L; Schwartz M; Manni M; Tarantino V; Pileri S; Ko YH; Cabrera ME; Horwitz S; Kim WS; Shustov A; Foss FM; Nagler A; Carson K; Pinter-Brown LC; Montoto S; Spina M; Feldman TA; Lechowicz MJ; Smith SM; Lansigan F; Gabus R; Vose JM; Advani RH;
    Br J Haematol; 2018 Jun; 181(6):760-769. PubMed ID: 29672827
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Classification of distinct subtypes of peripheral T-cell lymphoma unspecified, identified by chemokine and chemokine receptor expression: Analysis of prognosis.
    Ohshima K; Karube K; Kawano R; Tsuchiya T; Suefuji H; Yamaguchi T; Suzumiya J; Kikuchii M
    Int J Oncol; 2004 Sep; 25(3):605-13. PubMed ID: 15289861
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS)].
    Kinoshita T
    Nihon Rinsho; 2014 Mar; 72(3):512-8. PubMed ID: 24724412
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Molecular Insights Into Pathogenesis of Peripheral T Cell Lymphoma: a Review.
    Lone W; Alkhiniji A; Manikkam Umakanthan J; Iqbal J
    Curr Hematol Malig Rep; 2018 Aug; 13(4):318-328. PubMed ID: 29951889
    [TBL] [Abstract][Full Text] [Related]  

  • 57. CD30 Expression by B and T Cells: A Frequent Finding in Angioimmunoblastic T-Cell Lymphoma and Peripheral T-Cell Lymphoma-Not Otherwise Specified.
    Onaindia A; Martínez N; Montes-Moreno S; Almaraz C; Rodríguez-Pinilla SM; Cereceda L; Revert JB; Ortega C; Tardio A; González L; García S; Camacho FI; González-Vela C; Piris MA
    Am J Surg Pathol; 2016 Mar; 40(3):378-85. PubMed ID: 26574847
    [TBL] [Abstract][Full Text] [Related]  

  • 58. CDKN1B/p27 expression in peripheral T cell lymphoma not otherwise specified.
    Gazzola A; Sista MT; Agostinelli C; Righi S; Sapienza MR; Mannu C; Rossi M; Bacci F; Sabattini E; Went P; Zinzani PL; Pileri SA; Piccaluga PP
    J Clin Pathol; 2011 Jan; 64(1):83-7. PubMed ID: 21045237
    [TBL] [Abstract][Full Text] [Related]  

  • 59. STX11 functions as a novel tumor suppressor gene in peripheral T-cell lymphomas.
    Yoshida N; Tsuzuki S; Karube K; Takahara T; Suguro M; Miyoshi H; Nishikori M; Shimoyama M; Tsukasaki K; Ohshima K; Seto M
    Cancer Sci; 2015 Oct; 106(10):1455-62. PubMed ID: 26176172
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Morphoproteomics identifies constitutive activation of the mTORC2/Akt and NF-κB pathways and expressions of IGF-1R, Sirt1, COX-2, and FASN in peripheral T-cell lymphomas: pathogenetic implications and therapeutic options.
    Quesada AE; Nguyen ND; Rios A; Brown RE
    Int J Clin Exp Pathol; 2014; 7(12):8732-9. PubMed ID: 25674239
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.